Summary & Overview
HCPCS J3410: Injection of Hydroxyzine HCl, up to 25 mg
HCPCS Level II code J3410 denotes administration of hydroxyzine hydrochloride, up to 25 mg, delivered by injection. As a commonly used antihistamine with sedative properties, this medication is administered across outpatient settings including physician offices, emergency departments, and ambulatory surgical centers. Nationally, accurate coding of parenteral medications like J3410 affects claims processing, beneficiary cost-sharing, and inventory tracking for clinics and hospitals.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of billing benchmarks, payer coverage patterns, clinical context for use, and where J3410 appears in service lines. The publication highlights common billing considerations such as appropriate service type designations and typical sites of service for injectable medications.
The piece is intended for billing professionals, clinicians involved in medication administration, and policy analysts seeking a national perspective on how injectable non-controlled antihistamines are coded and reimbursed. Data not available in the input is noted where applicable; the focus remains on clarifying the code’s clinical meaning, service context, and payer landscape.
Billing Code Overview
HCPCS Level II code J3410 represents an injection of hydroxyzine hydrochloride, up to 25 mg. This code describes a single administration of the antihistamine medication hydroxyzine HCl for indications that may include allergy symptoms, anxiety adjunctive therapy, or as a sedative prior to procedures.
-
Service type: Medication administration (parenteral injection)
-
Typical site of service: Outpatient clinic, emergency department, physician office, or ambulatory surgical center, depending on clinical context and local practice patterns.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an outpatient clinic, urgent care, or emergency department with moderate to severe pruritus, acute allergic reaction with itching, or as an adjunct for sedation or anxiety prior to a minor procedure. The clinician documents the indication (for example, acute urticaria with intense pruritus), reviews allergies and airway risk, obtains informed consent, and prepares an intramuscular or intravenous injection of hydroxyzine hydrochloride up to 25 mg (J3410). Vital signs and sedation monitoring are recorded before and after administration. The medication is administered by a licensed nurse or clinician; post‑administration monitoring for sedation, hypotension, or paradoxical reactions is performed. Billing is submitted for the single‑drug injectable supply using J3410, with any applicable modifiers to report service circumstances (for example, an unrelated evaluation and management visit or a discarded portion). Typical sites of service include outpatient clinic, urgent care, emergency department, and same‑day procedural areas.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable E/M service by the same physician on the same day of the procedure | Use when a documented evaluation and management visit is provided on the same day as and meets criteria for a separate service |